By analyzing 28 studies involving use of HMGcoA reductase inhibitors or other anti-lipidemic agents in more than 100,000 patients, researchers have concluded that those patients given the HMGcoA inhibitors were 0.76 times as likely to develop strokes as those in the control groups. The stroke rate in patients given fibrates, resins or dietary intervention did not significantly differ from the control groups.
Colesevelam is supplied as an off-white tablet containing. It should always be taken with a liquid and a meal. The dose of colesevelam may be increased, depending upon the desired therapeutic effect.